Retrospective Review of Reduce Data to Determine the Utility of PSADv While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage
This is a review of previously published data from a large prostate cancer prevention study
known as REDUCE that utilized a 5 ARI, dutasteride. It is the investigators intention to
review whether PSA velocity (change over time) will predict the presence of prostate cancer
and its grade and stage (severity) by two year biopsy. The investigator will review and
compare data to a previously published study of similar design with finasteride.
Observational Model: Case Control, Time Perspective: Retrospective
Steven I Cohen, MD
University Urological Associates Inc.
United States: Institutional Review Board
|Division of Urology, Brown University||Providence, Rhode Island 02903|